Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Haematology, Neurological, Diabetes Mellitus, Other), by Vector (Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-viral (Naked DNA, Gene Gun, Electroporation, Lipofection)), by Techniques (Gene Augmentation Therapy, Gene Replacement Therapy), by Participants (Small/Medium Pharma & Biotech, Universities & Research Institutes, Hospitals, Government & Public Bodies, Big Pharma) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
The Gene Therapy R&D Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Diversification of Technical Risks is a Key Strategy for Winning in the Gene Therapy R&D Market The majority of the biotechnology firms associated with gene therapies are established across a special technology platform i.e., novel viral capsid that could have favoured acceptance in an organ system. Most of them continue to de-risk the technology as soon as possible, with the underlying technology platform that gave birth to the gene therapy candidates often being the main feature across chosen indications. This focuses risk on the technology platform & exposes the company to a catastrophic event that would have a negative impact on the entire portfolio. When it comes to this challenge, early-stage gene therapy firms often lack this choice; and once the newly founded technology achieves traction, executives will often follow adjacent plans that diversify risk & optimize prospects for the company. Companies working on gene therapies may evolve distinct viral delivery vectors or technologies for in vivo & ex vivo applications. Furthermore, balancing spending levels between developed and emerging channels, as well as deciding whether to implement new innovations in-house or obtain them from outside sources, is difficult. Importantly, strategic decisions about technology should be matched with strategic decisions about indication mix to ensure a clear future path.
400 million People Suffer from One or More of Over 7,000 Rare Diseases About 400 million people globally suffer from one or more of over 7,000 rare diseases reported. Rare disease affects between 3.5% and 5.9% of the world’s population. The cause of 72% of rare diseases is hereditary, while others are triggered by pathogens (bacterial or viral), asthma, and environmental conditions, or are degenerative and proliferative in nature. Approximately, 70% of genetic rare diseases begin in childhood. Symptoms that are relatively normal can obscure underlying unusual disorders, resulting in misdiagnosis and treatment delays. The lack of loss of mobility caused by the chronic, worsening, degenerative, and often life-threatening manifestations of the condition has a significant effect on the patient’s quality of life. Thus, the rising number of rare disease patients around the world is anticipated to drive the gene therapy application in this segment during the forecast period.
The costliest medication in the world right now is Zolgensma, which treats spinal muscular atrophy, a rare hereditary illness that harms nerve cells and causes muscle degeneration. The life-saving medication’s one-time treatment for a young child costs $2.1 million. While Zolgensma’s excessive cost is an incongruity at present times, there will be several cell & gene therapies available over the next ten years, with prices ranging from thousands to millions of dollars for a single dose. By 2025, the FDA is anticipated to approve 10-20 cell & gene therapies annually.
Asia-Pacific Region Remains a Hub for Advanced Therapy Medicinal Products With the many legislative initiatives put forth by the governments to promote innovation, research, and development in Asia-Pacific, the area remains a hub for advanced therapy medicinal products. Over the course of the projected period, this is expected to propel market expansion. A*STAR’s Bioprocessing Technology Institute (BTI) and WuXi Advanced Therapies, a fully owned subsidiary of WuXi AppTec, established a new agreement in May 2022 to introduce WuXi ATU’s unique Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology in the Asia-Pacific area. WuXi ATU will provide the resources, tools, funds, and training necessary to advance the development and commercialization of TESSA technology in Singapore as part of this partnership. BTI will support WuXi ATU in its research and development of cell and gene therapy in Singapore by providing research skills, facilities, and access to its network of partners.
What Are These Questions You Should Ask Before Buying A Market Research Report? • How is the gene therapy R&D market evolving? • What is driving and restraining the gene therapy R&D market? • How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032? • How will the market shares for each gene therapy R&D submarket develop from 2022 to 2032? • What will be the main driver for the overall market from 2022 to 2032? • Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others? • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032? • Who are the leading players and what are their prospects over the forecast period? • What are the gene therapy R&D projects for these leading companies? • How will the industry evolve during the period between 2022 and 2032? What are the implication of gene therapy R&D projects taking place now and over the next 10 years? • Is there a greater need for product commercialisation to further scale the gene therapy R&D market? • Where is the gene therapy R&D market heading? And how can you ensure you are at the forefront of the market? • What can be the best investment options for new product and service lines? • What are the key prospects for moving companies into a new growth path? C-suite?
You need to discover how this will impact the Gene Therapy R&D Market today, and over the next 10 years: • Our 461-page report provides 169 tables and 228 charts/graphs exclusively to you. • The report highlights key lucrative areas in the industry so you can target them – NOW. • Contains in-depth analysis of global, regional and national sales and growth • Highlights for you the key successful trends, changes and revenue projections made by your competitors
This report tells you TODAY how the Gene Therapy R&D Market will develop in the next 10 years, and in-line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Delivers exclusive COVID-19 variations economic data specific to your market.
To access the data contained in this document please email contactus@visiongain.com
Forecasts to 2032 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), PEST analysis, Porter’s Five Forces and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U’ are discussed in this report.
Participants • Small/Medium Pharma & Biotech • Universities & Research Institutes • Hospitals • Government & Public Bodies • Big Pharma
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:
North America • U.S. • Canada
Europe • Germany • UK • France • Italy • Spain • Russia • Rest of Europe
Asia Pacific • Japan • China • India • Australia • South Korea • South East Asia • Rest of Asia Pacific
Latin America • Brazil • Mexico • Rest of Latin America
The report also includes profiles and for some of the leading companies in the Gene Therapy R&D Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth • Astellas Pharma Inc. • American Gene Technologies • Applied Genetic • Bayer • Benitec BioPharma • Biogen • Bluebird Bio • Bristol Myers Squibb • Calimmune, Inc. (CSL Behiring) • Cellectis • F. Hoffmann-La Roche Ltd. • GeneQuine Biotherapeutics • GenSight Biologics • Gilead Lifesciences, Inc. • Novartis AG • OCUGEN, INC. • Orchard Therapeutics • Oxford Biomedica • Pfizer, Inc. • REGENXBIO Inc. • Sangamo Therapeutics, Inc. • Sanofi • Sarepta Therapeutics, Inc. • Spark Therapeutics (Subsidiary of Roche) • Takeda Pharmaceuticals • Taysha GTx • Transgene • UniQure NV • Voyager Therapeutics • ViGeneron.
Overall world revenue for Gene Therapy R&D Market, 2022 to 2032 in terms of value the market will surpass US$2,126.3 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Gene Therapy R&D Market, 2022 to 2032 Market report helps you? In summary, our 460+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Gene Therapy R&D Market, 2022 to 2032 Market, with forecasts for disease, vector, techniques, and participants size each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2032 for 5 regional and 18 key national markets – See forecasts for the Gene Therapy R&D Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 30 of the major companies involved in the Gene Therapy R&D Market, 2022 to 2032 Market.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Gene Therapy R&D Market, 2022 to 2032 Market and leading companies. You will find data, trends and predictions.
Buy our report today Gene Therapy R&D Market Report 2022-2032: Forecasts by Disease (Cancer, Rare Diseases (Oncologic, Non-oncologic), Cardiovascular Diseases, Ophthalmic Diseases, Haematology, Neurological, Diabetes Mellitus, Other), by Vector (Viral (Retrovirus, Adenovirus, AAV, Lentivirus, Others), Non-viral (Naked DNA, Gene Gun, Electroporation, Lipofection)), by Techniques (Gene Augmentation Therapy, Gene Replacement Therapy), by Participants (Small/Medium Pharma & Biotech, Universities & Research Institutes, Hospitals, Government & Public Bodies, Big Pharma) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview 1.1 Objectives of the Study 1.2 Introduction to Gene Therapy R&D Market 1.3 What This Report Delivers 1.4 Why You Should Read This Report 1.5 Key Questions Answered By This Analytical Report Include: 1.6 Who is This Report For? 1.7 Methodology 1.7.1 Market Definitions 1.7.2 Market Evaluation & Forecasting Methodology 1.7.3 Data Validation 1.7.3.1 Primary Research 1.7.3.2 Secondary Research 1.8 Frequently Asked Questions (FAQs) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2 Executive Summary
3 Market Overview 3.1 Key Findings 3.2 Market Dynamics 3.3 Drivers 3.3.1 Robust Gene Therapy Pipeline to Boost Growth 3.3.2 Technological Advancements to Fuel Market Growth 3.3.3 Increasing Investments by Major Players 3.3.3.1 Financings by Deal Type, 2021 3.3.3.2 Financings by Deal Type, 2020 3.3.4 Growing Prevalence of Targeted Diseases Treatment 3.4 Restraints/Challenges 3.4.1 Cell & Gene Therapies Target Specific Diseases 3.4.2 High Cost to Stifle Gene Therapy R&D Growth 3.4.3 Regulatory Scenarios to Challenge Industry Growth 3.5 Opportunities 3.5.1 Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities 3.5.2 Facility Expansion Anticipated to Offer Lucrative Growth Prospects 3.6 COVID-19 Impact Analysis 3.7 Porter’s Five Forces Analysis 3.7.1 Bargaining Power of Suppliers 3.7.2 Bargaining Power of Buyers 3.7.3 Competitive Rivalry 3.7.4 Threat of Substitute Products 3.7.5 Threat of New Entrants 3.8 PEST Analysis 3.8.1 Political Factors Impacting Gene Therapy R&D Market 3.8.2 Economic Factors Impacting Gene Therapy R&D Market 3.8.3 Social Factors Impacting Gene Therapy R&D Market 3.8.4 Technological Factors Impacting Gene Therapy R&D Market 3.9 Pipeline Analysis 3.9.1 Projected Launch Year, 2022 3.9.2 Projected Launch Year, 2023 3.9.3 Projected Launch Year, 2024 3.9.4 Projected Launch Year, 2025 3.9.5 Gene Therapy Pipeline Assets Forecast till 2026 3.9.6 Clinical Trials Activity by Key Areas 3.9.6.1 Industry Sponsored Trials by Phase 3.9.6.2 Academic and Government Sponsored Trials by Phase 3.9.6.3 Rare Diseases Clinical Activity by Indication 3.9.6.4 Prevalent Diseases Clinical Activity by Indication 3.9.6.5 Next-Gen Therapies Competition by Region 3.9.6.6 Indications With Significant Clinical Activity
4 Gene Therapy R&D Market Analysis by Disease 4.1 Key Findings 4.2 Disease Segment Growth Prospects 4.3 Gene Therapy R&D Market Size Estimation and Forecast by Disease 4.4 Cancer 4.4.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.4.2 Market Share by Region, 2022 & 2032 (%) 4.5 Rare Diseases 4.5.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.5.2 Market Share by Region, 2022 & 2032 (%) 4.5.3 Rare Diseases Segment Market Forecast by Type, 2022-2032 (US$ Mn) 4.6 Cardiovascular Diseases 4.6.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.6.2 Market Share by Region, 2022 & 2032 (%) 4.7 Ophthalmic Diseases 4.7.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.7.2 Market Share by Region, 2022 & 2032 (%) 4.8 Hematology 4.8.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.8.2 Market Share by Region, 2022 & 2032 (%) 4.9 Neurological 4.9.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.9.2 Market Share by Region, 2022 & 2032 (%) 4.10 Diabetes Mellitus 4.10.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.10.2 Market Share by Region, 2022 & 2032 (%) 4.11 Other Diseases 4.11.1 Market Forecast by Region, 2022-2032 (US$ Mn) 4.11.2 Market Share by Region, 2022 & 2032 (%)
6 Gene Therapy R&D Market Analysis by Techniques 6.1 Key Findings 6.2 Techniques Segment Growth Prospects 6.3 Gene Therapy R&D Market Size Estimation and Forecast by Techniques 6.4 Gene Augmentation Therapy 6.4.1 Market Forecast by Region, 2022-2032 (US$ Mn) 6.4.2 Market Share by Region, 2022 & 2032 (%) 6.5 Gene Replacement Therapy 6.5.1 Market Forecast by Region, 2022-2032 (US$ Mn) 6.5.2 Market Share by Region, 2022 & 2032 (%)
7 Gene Therapy R&D Market Analysis by Participants 7.1 Key Findings 7.2 Participants Segment Growth Prospects 7.3 Gene Therapy R&D Market Size Estimation and Forecast by Participants 7.4 Small/Medium Pharma & Biotech 7.4.1 Market Forecast by Region, 2022-2032 (US$ Mn) 7.4.2 Market Share by Region, 2022 & 2032 (%) 7.5 Universities & Research Institutes 7.5.1 Market Forecast by Region, 2022-2032 (US$ Mn) 7.5.2 Market Share by Region, 2022 & 2032 (%) 7.6 Hospitals, Government & Public Bodies 7.6.1 Market Forecast by Region, 2022-2032 (US$ Mn) 7.6.2 Market Share by Region, 2022 & 2032 (%) 7.7 Big Pharma 7.7.1 Market Forecast by Region, 2022-2032 (US$ Mn) 7.7.2 Market Share by Region, 2022 & 2032 (%)
8 Gene Therapy R&D Market Analysis by Region 8.1 Key Findings 8.2 Regional Market Size Estimation and Forecast 8.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
9 North America Gene Therapy R&D Market Analysis 9.1 Key Findings 9.2 North America Gene Therapy R&D Market Attractiveness Index 9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn) 9.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn) 9.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn) 9.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn) 9.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn) 9.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn) 9.9 U.S. 9.10 Canada
10 Europe Gene Therapy R&D Market Analysis 10.1 Key Findings 10.2 Europe Gene Therapy R&D Market Attractiveness Index 10.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn) 10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn) 10.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn) 10.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn) 10.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn) 10.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn) 10.9 Germany 10.10 UK 10.11 France 10.12 Italy 10.13 Spain 10.14 Russia 10.15 Rest of Europe
11 Asia Pacific Gene Therapy R&D Market Analysis 11.1 Key Findings 11.2 Asia Pacific Gene Therapy R&D Market Attractiveness Index 11.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn) 11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn) 11.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn) 11.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn) 11.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn) 11.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn) 11.9 Japan 11.10 China 11.11 India 11.12 Australia 11.13 South Korea 11.14 South East Asia 11.15 Rest of Asia Pacific
12 Latin America Gene Therapy R&D Market Analysis 12.1 Key Findings 12.2 Latin America Gene Therapy R&D Market Attractiveness Index 12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn) 12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn) 12.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn) 12.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn) 12.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn) 12.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn) 12.9 Brazil 12.10 Mexico 12.11 Rest of Latin America
13 MEA Gene Therapy R&D Market Analysis 13.1 Key Findings 13.2 MEA Gene Therapy R&D Market Attractiveness Index 13.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn) 13.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ Mn) 13.5 Market Size Estimation and Forecast by Disease, 2022-2032 (US$ Mn) 13.6 Market Size Estimation and Forecast by Vector, 2022-2032 (US$ Mn) 13.7 Market Size Estimation and Forecast by Techniques, 2022-2032 (US$ Mn) 13.8 Market Size Estimation and Forecast by Participants, 2022-2032 (US$ Mn) 13.9 GCC 13.10 South Africa 13.11 Rest of MEA
14 Company Profiles 14.1 Strategic Choices for Winning in Gene Therapy R&D Market 14.1.1 Diversification of Technical Risks 14.1.2 How to Achieve Long Term Benefits to Patients 14.1.3 Building Digital Capabilities 14.1.4 Mergers & Acquisitions to Offer Lucrative Growth Prospects for Players Across the Value Chain 14.2 Approved Cellular & Gene Therapy Products as of March 2021 14.3 Ongoing Gene Therapy Clinical Trials by Companies 14.4 Gene Therapy Companies Market Capitalization 14.5 Strategic Outlook 14.6 Astellas Pharma Inc. 14.6.1 Company Snapshot 14.6.2 Company Overview 14.6.3 Financial Analysis 14.6.3.1 Net Revenue, 2015-2021 14.6.3.2 Regional Market Shares, 2020 14.6.3.3 Gross Profit, 2015-2021 14.6.3.4 R&D, 2015-2021 14.6.4 Product Benchmarking 14.6.5 Strategic Outlook 14.7 American Gene Technologies 14.7.1 Company Snapshot 14.7.2 Company Overview 14.7.3 Product Benchmarking 14.7.4 Strategic Outlook 14.8 Applied Genetic 14.8.1 Company Snapshot 14.8.2 Company Overview 14.8.3 Financial Analysis 14.8.3.1 Net Revenue, 2015-2021 14.8.3.2 Gross Profit, 2015-2021 14.8.3.3 R&D, 2015-2021 14.8.4 Product Benchmarking 14.8.5 Strategic Outlook 14.9 Bayer 14.9.1 Company Snapshot 14.9.2 Company Overview 14.9.3 Financial Analysis 14.9.3.1 Net Revenue, 2015-2021 14.9.3.2 Regional Market Shares, 2021 14.9.3.3 Gross Profit, 2015-2021 14.9.3.4 R&D, 2015-2021 14.9.4 Product Benchmarking 14.9.5 Strategic Outlook 14.10 Benitec BioPharma 14.10.1 Company Snapshot 14.10.2 Company Overview 14.10.3 Financial Analysis 14.10.3.1 Net Revenue, 2015-2021 14.10.3.2 Gross Profit, 2015-2021 14.10.3.3 R&D, 2015-2021 14.10.4 Product Benchmarking 14.10.5 Strategic Outlook 14.11 Biogen 14.11.1 Company Snapshot 14.11.2 Company Overview 14.11.3 Financial Analysis 14.11.3.1 Net Revenue, 2015-2021 14.11.3.2 Regional Market Shares, 2021 14.11.3.3 Gross Profit, 2015-2021 14.11.3.4 R&D, 2015-2021 14.11.4 Product Benchmarking 14.11.5 Strategic Outlook 14.12 Bluebird Bio 14.12.1 Company Snapshot 14.12.2 Company Overview 14.12.3 Financial Analysis 14.12.3.1 Net Revenue, 2015-2021 14.12.3.2 Gross Profit, 2015-2019 14.12.3.3 R&D, 2015-2021 14.12.4 Product Benchmarking 14.12.5 Strategic Outlook 14.13 Bristol Myers Squibb 14.13.1 Company Snapshot 14.13.2 Company Overview 14.13.3 Financial Analysis 14.13.3.1 Net Revenue, 2015-2021 14.13.3.2 Regional Market Shares, 2021 14.13.3.3 Gross Profit, 2015-2021 14.13.3.4 R&D, 2015-2021 14.13.4 Product Benchmarking 14.13.5 Strategic Outlook 14.14 Calimmune, Inc. (CSL Behiring) 14.14.1 Company Snapshot 14.14.2 Company Overview 14.14.3 Product Benchmarking 14.14.4 Strategic Outlook 14.15 Cellectis 14.15.1 Company Snapshot 14.15.2 Company Overview 14.15.3 Financial Analysis 14.15.3.1 Net Revenue, 2015-2021 14.15.3.2 Gross Profit, 2015-2021 14.15.3.3 R&D, 2015-2021 14.15.4 Product Benchmarking 14.15.5 Strategic Outlook 14.16 F. Hoffmann-La Roche Ltd. 14.16.1 Company Snapshot 14.16.2 Company Overview 14.16.3 Financial Analysis 14.16.3.1 Net Revenue, 2015-2021 14.16.3.2 Gross Profit, 2015-2021 14.16.3.3 R&D, 2015-2021 14.16.4 Product Benchmarking 14.16.5 Strategic Outlook 14.17 GenSight Biologics 14.17.1 Company Snapshot 14.17.2 Company Overview 14.17.3 Product Benchmarking 14.17.4 Strategic Outlook 14.18 Gilead Lifesciences, Inc. 14.18.1 Company Snapshot 14.18.2 Company Overview 14.18.3 Financial Analysis 14.18.3.1 Net Revenue, 2015-2021 14.18.3.2 Gross Profit, 2015-2021 14.18.3.3 R&D, 2015-2021 14.18.4 Product Benchmarking 14.18.5 Strategic Outlook 14.19 Novartis AG 14.19.1 Company Snapshot 14.19.2 Company Overview 14.19.3 Financial Analysis 14.19.3.1 Net Revenue, 2015-2021 14.19.3.2 Regional Market Shares, 2021 14.19.3.3 Gross Profit, 2015-2021 14.19.3.4 R&D, 2015-2021 14.19.4 Product Benchmarking 14.19.5 Strategic Outlook 14.20 Orchard Therapeutics 14.20.1 Company Snapshot 14.20.2 Company Overview 14.20.3 Product Benchmarking 14.20.4 Strategic Outlook 14.21 Oxford Biomedica 14.21.1 Company Snapshot 14.21.2 Company Overview 14.21.3 Financial Analysis 14.21.3.1 Net Revenue, 2015-2021 14.21.3.2 Regional Market Shares, 2021 14.21.4 Product Benchmarking 14.21.5 Strategic Outlook 14.22 Pfizer, Inc. 14.22.1 Company Snapshot 14.22.2 Company Overview 14.22.3 Financial Analysis 14.22.3.1 Net Revenue, 2015-2021 14.22.3.2 Regional Market Shares, 2021 14.22.3.3 Gross Profit, 2015-2021 14.22.3.4 R&D, 2015-2021 14.22.4 Product Benchmarking 14.22.5 Strategic Outlook 14.23 REGENXBIO Inc. 14.23.1 Company Snapshot 14.23.2 Company Overview 14.23.3 Financial Analysis 14.23.3.1 Net Revenue, 2015-2021 14.23.3.2 Gross Profit, 2015-2021 14.23.3.3 R&D, 2015-2021 14.23.4 Product Benchmarking 14.23.5 Strategic Outlook 14.24 Sangamo Therapeutics, Inc. 14.24.1 Company Snapshot 14.24.2 Company Overview 14.24.3 Financial Analysis 14.24.3.1 Net Revenue, 2015-2021 14.24.3.2 Gross Profit, 2015-2021 14.24.3.3 R&D, 2015-2021 14.24.4 Product Benchmarking 14.24.5 Strategic Outlook 14.25 Sanofi 14.25.1 Company Snapshot 14.25.2 Company Overview 14.25.3 Financial Analysis 14.25.3.1 Net Revenue, 2015-2021 14.25.3.2 Regional Market Shares, 2021 14.25.3.3 Gross Profit, 2015-2021 14.25.3.4 R&D, 2015-2021 14.25.4 Product Benchmarking 14.25.5 Strategic Outlook 14.26 Spark Therapeutics (Subsidiary of Roche) 14.26.1 Company Snapshot 14.26.2 Company Overview 14.26.3 Product Benchmarking 14.26.4 Strategic Outlook 14.27 Takeda Pharmaceuticals 14.27.1 Company Snapshot 14.27.2 Company Overview 14.27.3 Financial Analysis 14.27.3.1 Net Revenue, 2015-2021 14.27.3.2 Regional Market Shares, 2021 14.27.3.3 Gross Profit, 2015-2021 14.27.3.4 R&D, 2015-2021 14.27.4 Product Benchmarking 14.27.5 Strategic Outlook 14.28 Transgene 14.28.1 Company Snapshot 14.28.2 Company Overview 14.28.3 Product Benchmarking 14.28.4 Strategic Outlook 14.29 UniQure NV 14.29.1 Company Snapshot 14.29.2 Company Overview 14.29.3 Financial Analysis 14.29.3.1 Net Revenue, 2015-2021 14.29.3.2 Gross Profit, 2015-2021 14.29.3.3 R&D, 2015-2021 14.29.4 Product Benchmarking 14.29.5 Strategic Outlook 14.30 Voyager Therapeutics 14.30.1 Company Snapshot 14.30.2 Company Overview 14.30.3 Financial Analysis 14.30.3.1 Net Revenue, 2015-2021 14.30.3.2 Gross Profit, 2015-2021 14.30.3.3 R&D, 2015-2021 14.30.4 Product Benchmarking 14.30.5 Strategic Outlook 14.31 ViGeneron 14.31.1 Company Snapshot 14.31.2 Company Overview 14.31.3 Product Benchmarking 14.31.4 Strategic Outlook 14.32 GeneQuine Biotherapeutics 14.32.1 Company Snapshot 14.32.2 Company Overview 14.32.3 Product Benchmarking 14.32.4 Strategic Outlook 14.33 OCUGEN, INC. 14.33.1 Company Snapshot 14.33.2 Company Overview 14.33.3 Product Benchmarking 14.33.4 Strategic Outlook 14.34 Taysha GTx 14.34.1 Company Snapshot 14.34.2 Company Overview 14.34.3 Product Benchmarking 14.34.4 Strategic Outlook 14.35 Sarepta Therapeutics, Inc. 14.35.1 Company Snapshot 14.35.2 Company Overview 14.35.3 Product Benchmarking 14.35.4 Strategic Outlook
15 Conclusion and Recommendations 15.1 Concluding Remarks from Visiongain 15.2 Recommendations for Market Players
List of Tables Table 1 Gene Therapy R&D Market Snapshot, 2022 & 2032 (US$ million, CAGR %) Table 2 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery Table 3 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery Table 4 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery Table 5 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery Table 6 Gene Therapy Pipeline: Q1-Q4, 2022 Table 7 Gene Therapy Pipeline: Q1-Q4, 2023 Table 8 Gene Therapy Pipeline: Q1-Q4, 2024 Table 9 Gene Therapy Pipeline: Q1-Q4, 2025 Table 10 Gene Therapy Pipeline Assets Forecast till 2026 (US$ mn) Table 11 Global Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%) Table 12 Cancer Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR %) Table 13 Rare Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 14 Global Gene Therapy R&D Market Forecast by Rare Diseases, 2022-2032 (US$ mn, AGR%, CAGR %) Table 15 Cardiovascular Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 16 Ophthalmic Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 17 Hematology Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 18 Neurological Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 19 Diabetes Mellitus Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 20 Other Diseases Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 21 Global Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 22 Viral Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 23 Global Gene Therapy R&D Market Forecast by Viral Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 24 Viral Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 25 Global Gene Therapy R&D Market Forecast by Non-viral, 2022-2032 (US$ mn, AGR%, CAGR%) Table 26 Global Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%) Table 27 Gene Augmentation Therapy Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 28 Gene Replacement Therapy Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 29 Global Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%) Table 30 Small/Medium Pharma & Biotech Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 31 Universities & Research Institutes Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 32 Hospitals, Government & Public Bodies Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 33 Big Pharma Segment Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 34 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%) Table 35 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery Table 36 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery Table 37 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery Table 38 Global Gene Therapy R&D Market Forecast by Region, 2022-2032 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery Table 39 North America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR %) Table 40 North America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%) Table 41 North America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 42 North America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%) Table 43 North America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%) Table 44 U.S. Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 45 Canada Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 46 Europe Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%) Table 47 Europe Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR %) Table 48 Europe Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 49 Europe Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%) Table 50 Europe Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%) Table 51 Germany Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 52 UK Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 53 France Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 54 Italy Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 55 Spain Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 56 Russia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 57 Rest of Europe Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %) Table 58 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%) Table 59 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%) Table 60 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 61 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%) Table 62 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%) Table 63 Japan Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR %) Table 64 China Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 65 India Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 66 Australia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 67 South Korea Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 68 South East Asia Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 69 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 70 Latin America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR%) Table 71 Latin America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%) Table 72 Latin America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 73 Latin America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%) Table 74 Latin America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%) Table 75 Brazil Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 76 Mexico Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 77 Rest of Latin America Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 78 MEA Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ mn, AGR%, CAGR %) Table 79 MEA Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ mn, AGR%, CAGR%) Table 80 MEA Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ mn, AGR%, CAGR%) Table 81 MEA Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ mn, AGR%, CAGR%) Table 82 MEA Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ mn, AGR%, CAGR%) Table 83 GCC Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 84 South Africa Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 85 Rest of MEA Gene Therapy R&D Market Forecast, 2022-2032 (US$ mn, AGR%, CAGR%) Table 86 Gene Therapy R&D Market Strategic Outlook Table 87 Astellas Pharma Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 88 Astellas Pharma Inc.: Product Benchmarking Table 89 American Gene Technologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 90 American Gene Technologies: Product Benchmarking Table 91 Applied Genetic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 92 Applied Genetic: Product Benchmarking Table 93 Applied Genetic: Strategic Outlook Table 94 Bayer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 95 Bayer: Product Benchmarking Table 96 Bayer: Strategic Outlook Table 97 Benitec BioPharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 98 Benitec BioPharma: Product Benchmarking Table 99 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 100 Biogen: Product Benchmarking Table 101 Biogen: Strategic Outlook Table 102 Bluebird Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 103 Bluebird Bio: Product Benchmarking Table 104 Bluebird Bio: Strategic Outlook Table 105 Bristol Myers Squibb: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 106 Bristol Myers Squibb: Product Benchmarking Table 107 Bristol Myers Squibb: Strategic Outlook Table 108 Calimmune, Inc. (CSL Behiring): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 109 Calimmune, Inc. (CSL Behiring): Product Benchmarking Table 110 Calimmune, Inc. (CSL Behiring): Strategic Outlook Table 111 Cellectis: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 112 Cellectis: Product Benchmarking Table 113 Cellectis: Strategic Outlook Table 114 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 115 F. Hoffmann-La Roche Ltd.: Product Benchmarking Table 116 F. Hoffmann-La Roche Ltd.: Strategic Outlook Table 117 GenSight Biologics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 118 GenSight Biologics: Product Benchmarking Table 119 Gilead Lifesciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 120 Gilead Lifesciences, Inc.: Product Benchmarking Table 121 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 122 Novartis AG: Product Benchmarking Table 123 Novartis AG: Strategic Outlook Table 124 Orchard Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 125 Orchard Therapeutics: Product Benchmarking Table 126 Orchard Therapeutics: Strategic Outlook Table 127 Oxford Biomedica: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 128 Oxford Biomedica: Product Benchmarking Table 129 Oxford Biomedica: Strategic Outlook Table 130 Pfizer, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 131 Pfizer, Inc.: Product Benchmarking Table 132 Pfizer, Inc.: Strategic Outlook Table 133 REGENXBIO Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 134 REGENXBIO Inc.: Product Benchmarking Table 135 REGENXBIO Inc.: Strategic Outlook Table 136 Sangamo Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 137 Sangamo Therapeutics, Inc.: Product Benchmarking Table 138 Sangamo Therapeutics, Inc.: Strategic Outlook Table 139 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 140 Sanofi: Product Benchmarking Table 141 Sanofi: Strategic Outlook Table 142 Spark Therapeutics (Subsidiary of Roche): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 143 Spark Therapeutics (Subsidiary of Roche): Product Benchmarking Table 144 Spark Therapeutics (Subsidiary of Roche): Strategic Outlook Table 145 Takeda Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 146 Takeda Pharmaceuticals: Product Benchmarking Table 147 Takeda Pharmaceuticals: Strategic Outlook Table 148 Transgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 149 Transgene: Product Benchmarking Table 150 UniQure NV: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 151 UniQure NV: Product Benchmarking Table 152 UniQure NV: Strategic Outlook Table 153 Voyager Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 154 Voyager Therapeutics: Product Benchmarking Table 155 Voyager Therapeutics: Strategic Outlook Table 156 ViGeneron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 157 ViGeneron: Product Benchmarking Table 158 ViGeneron: Strategic Outlook Table 159 GeneQuine Biotherapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 160 GeneQuine Biotherapeutics: Product Benchmarking Table 161 GeneQuine Biotherapeutics: Strategic Outlook Table 162 OCUGEN, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 163 OCUGEN, INC.: Product Benchmarking Table 164 OCUGEN, INC.: Strategic Outlook Table 165 Taysha GTx: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 166 Taysha GTx: Product Benchmarking Table 167 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 168 Sarepta Therapeutics, Inc.: Product Benchmarking Table 169 Sarepta Therapeutics, Inc.: Strategic Outlook
List of Figures Figure 1 Gene Therapy R&D Market Segmentation Figure 2 Gene Therapy R&D Market by Disease: Market Attractiveness Index Figure 3 Gene Therapy R&D Market by Vector: Market Attractiveness Index Figure 4 Gene Therapy R&D Market by Techniques: Market Attractiveness Index Figure 5 Gene Therapy R&D Market by Participants: Market Attractiveness Index Figure 6 Gene Therapy R&D Market Attractiveness Index by Region Figure 7 Gene Therapy R&D Market: Market Dynamics Figure 8 Gene, Cell & Tissue Bases Therapeutic Developers Financings by Deal Type, 2021 Figure 9 Gene, Cell & Tissue Bases Therapeutic Developers Financings by Deal Type, 2020 Figure 10 Rare vs. Prevalent: Industry Sponsored Trials Figure 11 Rare vs. Prevalent: Academic & Government Sponsored Trials Figure 12 COVID Impact Analysis: Gene Therapy R&D Market Recovery Scenarios Figure 13 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery Figure 14 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery Figure 15 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery Figure 16 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery Figure 17 Gene Therapy R&D Market: Porter’s Five Forces Analysis Figure 18 Gene Therapy R&D Market: PEST Analysis Figure 19 Industry Sponsored Trials by Phase Figure 20 Academic and Government Sponsored Trials by Phase Figure 21 Rare Diseases Clinical Activity by Indication Figure 22 Prevalent Diseases Clinical Activity by Indication Figure 23 Next-Gen Therapies Competition by Region Figure 24 Indications With Significant Clinical Activity Figure 25 Rare versus Prevalent Diseases Clinical Trials by Phase Figure 26 Gene Therapy R&D Market Attractiveness Index by Disease Figure 27 Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ million) Figure 28 Gene Therapy R&D Market Share Forecast by Disease, 2022, 2027, 2032 (%) Figure 29 Cancer Market Forecast by Region, 2022-2032 (US$ million) Figure 30 Cancer Market Share Forecast by Region, 2022 & 2032 (%) Figure 31 Rare Diseases Market Forecast by Region, 2022-2032 (US$ million) Figure 32 Rare Diseases Market Share Forecast by Region, 2022 & 2032 (%) Figure 33 Rare Diseases Segment Market Forecast by Type, 2022-2032 (US$ million) Figure 34 Cardiovascular Diseases Market Forecast by Region, 2022-2032 (US$ million) Figure 35 Cardiovascular Diseases Market Share Forecast by Region, 2022 & 2032 (%) Figure 36 Ophthalmic Diseases Market Forecast by Region, 2022-2032 (US$ million) Figure 37 Ophthalmic Diseases Market Share Forecast by Region, 2022 & 2032 (%) Figure 38 Hematology Market Forecast by Region, 2022-2032 (US$ million) Figure 39 Hematology Market Share Forecast by Region, 2022 & 2032 (%) Figure 40 Neurological Market Forecast by Region, 2022-2032 (US$ million) Figure 41 Neurological Market Share Forecast by Region, 2022 & 2032 (%) Figure 42 Diabetes Mellitus Market Forecast by Region, 2022-2032 (US$ million) Figure 43 Diabetes Mellitus Market Share Forecast by Region, 2022 & 2032 (%) Figure 44 Other Diseases Market Forecast by Region, 2022-2032 (US$ million) Figure 45 Other Diseases Market Share Forecast by Region, 2022 & 2032 (%) Figure 46 Gene Therapy R&D Market Attractiveness Index by Disease Figure 47 Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ million) Figure 48 Gene Therapy R&D Market Share Forecast by Vector, 2022, 2027, 2032 (%) Figure 49 Viral Market Forecast by Region, 2022-2032 (US$ million) Figure 50 Viral Market Share Forecast by Region, 2022 & 2032 (%) Figure 51 Viral Segment Market Forecast by Type, 2022-2032 (US$ million) Figure 52 Non-viral Market Forecast by Region, 2022-2032 (US$ million) Figure 53 Non-viral Market Share Forecast by Region, 2022 & 2032 (%) Figure 54 Non-viral Segment Market Forecast by Type, 2022-2032 (US$ million) Figure 55 Gene Therapy R&D Market Attractiveness Index by Techniques Figure 56 Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ million) Figure 57 Gene Therapy R&D Market Share Forecast by Techniques, 2022, 2027, 2032 (%) Figure 58 Gene Augmentation Therapy Market Forecast by Region, 2022-2032 (US$ million) Figure 59 Gene Augmentation Therapy Market Share Forecast by Region, 2022 & 2032 (%) Figure 60 Gene Replacement Therapy Market Forecast by Region, 2022-2032 (US$ million) Figure 61 Gene Replacement Therapy Market Share Forecast by Region, 2022 & 2032 (%) Figure 62 Gene Therapy R&D Market Attractiveness Index by Participants Figure 63 Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ million) Figure 64 Gene Therapy R&D Market Share Forecast by Participants, 2022, 2027, 2032 (%) Figure 65 Small/Medium Pharma & Biotech Market Forecast by Region, 2022-2032 (US$ million) Figure 66 Small/Medium Pharma & Biotech Market Share Forecast by Region, 2022 & 2032 (%) Figure 67 Universities & Research Institutes Market Forecast by Region, 2022-2032 (US$ million) Figure 68 Universities & Research Institutes Market Share Forecast by Region, 2022 & 2032 (%) Figure 69 Hospitals, Government & Public Bodies Market Forecast by Region, 2022-2032 (US$ million) Figure 70 Hospitals, Government & Public Bodies Market Share Forecast by Region, 2022 & 2032 (%) Figure 71 Big Pharma Market Forecast by Region, 2022-2032 (US$ million) Figure 72 Big Pharma Market Share Forecast by Region, 2022 & 2032 (%) Figure 73 Gene Therapy R&D Market Forecast by Region 2022 & 2032 (Revenue, CAGR%) Figure 74 Gene Therapy R&D Market Share Forecast by Region 2022, 2027, 2032(%) Figure 75 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn) Figure 76 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “V” Shaped Recovery Figure 77 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “U” Shaped Recovery Figure 78 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “W” Shaped Recovery Figure 79 Gene Therapy R&D Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): “L” Shaped Recovery Figure 80 North America Gene Therapy R&D Market Attractiveness Index Figure 81 North America Gene Therapy R&D Market by Region, 2022, 2027 & 2032 (US$ million) Figure 82 North America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ million) Figure 83 North America Gene Therapy R&D Market Share Forecast by Country, 2022 & 2032 (%) Figure 84 North America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ million) Figure 85 North America Gene Therapy R&D Market Share Forecast by Disease, 2022 & 2032 (%) Figure 86 North America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ million) Figure 87 North America Gene Therapy R&D Market Share Forecast by Vector, 2022 & 2032 (%) Figure 88 North America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ million) Figure 89 North America Gene Therapy R&D Market Share Forecast by Techniques, 2022 & 2032 (%) Figure 90 North America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ million) Figure 91 North America Gene Therapy R&D Market Share Forecast by Participants, 2022 & 2032 (%) Figure 92 U.S. Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 93 Canada Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 94 Europe Gene Therapy R&D Market Attractiveness Index Figure 95 Europe Gene Therapy R&D Market by Region, 2022, 2027 & 2032 (US$ million) Figure 96 Europe Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ million) Figure 97 Europe Gene Therapy R&D Market Share Forecast by Country, 2022 & 2032 (%) Figure 98 Europe Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ million) Figure 99 Europe Gene Therapy R&D Market Share Forecast by Disease, 2022 & 2032 (%) Figure 100 Europe Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ million) Figure 101 Europe Gene Therapy R&D Market Share Forecast by Vector, 2022 & 2032 (%) Figure 102 Europe Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ million) Figure 103 Europe Gene Therapy R&D Market Share Forecast by Techniques, 2022 & 2032 (%) Figure 104 Europe Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ million) Figure 105 Europe Gene Therapy R&D Market Share Forecast by Participants, 2022 & 2032 (%) Figure 106 Germany Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 107 UK Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 108 France Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 109 Italy Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 110 Spain Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 111 Russia Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 112 Rest of Europe Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 113 Asia Pacific Gene Therapy R&D Market Attractiveness Index Figure 114 Asia Pacific Gene Therapy R&D Market by Region, 2022, 2027 & 2032 (US$ million) Figure 115 Asia Pacific Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ million) Figure 116 Asia Pacific Gene Therapy R&D Market Share Forecast by Country, 2022 & 2032 (%) Figure 117 Asia Pacific Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ million) Figure 118 Asia Pacific Gene Therapy R&D Market Share Forecast by Disease, 2022 & 2032 (%) Figure 119 Asia Pacific Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ million) Figure 120 Asia Pacific Gene Therapy R&D Market Share Forecast by Vector, 2022 & 2032 (%) Figure 121 Asia Pacific Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ million) Figure 122 Asia Pacific Gene Therapy R&D Market Share Forecast by Techniques, 2022 & 2032 (%) Figure 123 Asia Pacific Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ million) Figure 124 Asia Pacific Gene Therapy R&D Market Share Forecast by Participants, 2022 & 2032 (%) Figure 125 Japan Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 126 China Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 127 India Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 128 Australia Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 129 South Korea Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 130 South East Asia Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 131 Rest of Asia Pacific Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 132 Latin America Gene Therapy R&D Market Attractiveness Index Figure 133 Latin America Gene Therapy R&D Market by Region, 2022, 2027 & 2032 (US$ million) Figure 134 Latin America Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ million) Figure 135 Latin America Gene Therapy R&D Market Share Forecast by Country, 2022 & 2032 (%) Figure 136 Latin America Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ million) Figure 137 Latin America Gene Therapy R&D Market Share Forecast by Disease, 2022 & 2032 (%) Figure 138 Latin America Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ million) Figure 139 Latin America Gene Therapy R&D Market Share Forecast by Vector, 2022 & 2032 (%) Figure 140 Latin America Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ million) Figure 141 Latin America Gene Therapy R&D Market Share Forecast by Techniques, 2022 & 2032 (%) Figure 142 Latin America Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ million) Figure 143 Latin America Gene Therapy R&D Market Share Forecast by Participants, 2022 & 2032 (%) Figure 144 Brazil Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 145 Mexico Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 146 Rest of Latin America Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 147 MEA Gene Therapy R&D Market Attractiveness Index Figure 148 MEA Gene Therapy R&D Market by Region, 2022, 2027 & 2032 (US$ million) Figure 149 MEA Gene Therapy R&D Market Forecast by Country, 2022-2032 (US$ million) Figure 150 MEA Gene Therapy R&D Market Share Forecast by Country, 2022 & 2032 (%) Figure 151 MEA Gene Therapy R&D Market Forecast by Disease, 2022-2032 (US$ million) Figure 152 MEA Gene Therapy R&D Market Share Forecast by Disease, 2022 & 2032 (%) Figure 153 MEA Gene Therapy R&D Market Forecast by Vector, 2022-2032 (US$ million) Figure 154 MEA Gene Therapy R&D Market Share Forecast by Vector, 2022 & 2032 (%) Figure 155 MEA Gene Therapy R&D Market Forecast by Techniques, 2022-2032 (US$ million) Figure 156 MEA Gene Therapy R&D Market Share Forecast by Techniques, 2022 & 2032 (%) Figure 157 MEA Gene Therapy R&D Market Forecast by Participants, 2022-2032 (US$ million) Figure 158 MEA Gene Therapy R&D Market Share Forecast by Participants, 2022 & 2032 (%) Figure 159 GCC Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 160 South Africa Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 161 Rest of MEA Gene Therapy R&D Market Forecast, 2022-2032 (US$ million) Figure 162 M&A activity in the cell and gene therapy industry, 2019 Figure 163 Gene Therapy Companies Market Cap in US$ bn Figure 164 Gene Therapy Companies Market Cap in US$ bn Figure 165 Astellas Pharma Inc.: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 166 Astellas Pharma Inc.: Regional Market Shares (%), 2020 Figure 167 Astellas Pharma Inc.: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 168 Astellas Pharma Inc.: R&D, 2015-2021 (US$ million, AGR%) Figure 169 Applied Genetic: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 170 Applied Genetic: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 171 Applied Genetic: R&D, 2015-2021 (US$ million, AGR%) Figure 172 Bayer: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 173 Bayer: Regional Market Shares (%), 2021 Figure 174 Bayer: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 175 Bayer: R&D, 2015-2021 (US$ million, AGR %) Figure 176 Benitec BioPharma: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 177 Benitec BioPharma: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 178 Benitec BioPharma: R&D, 2015-2021 (US$ million, AGR%) Figure 179 Biogen: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 180 Biogen: Regional Market Shares (%), 2021 Figure 181 Biogen: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 182 Biogen: R&D, 2015-2021 (US$ million, AGR%) Figure 183 Bluebird Bio: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 184 Bluebird Bio: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 185 Bluebird Bio: R&D, 2015-2021 (US$ million, AGR%) Figure 186 Bristol Myers Squibb: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 187 Bristol Myers Squibb: Regional Market Shares (%), 2021 Figure 188 Bristol Myers Squibb: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 189 Bristol Myers Squibb: R&D, 2015-2021 (US$ million, AGR%) Figure 190 Cellectis: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 191 Cellectis: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 192 Cellectis: R&D, 2015-2021 (US$ million, AGR%) Figure 193 F. Hoffmann-La Roche Ltd.: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 194 F. Hoffmann-La Roche Ltd.: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 195 F. Hoffmann-La Roche Ltd.: R&D, 2015-2021 (US$ million, AGR%) Figure 196 Gilead Lifesciences, Inc.: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 197 Gilead Lifesciences, Inc.: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 198 Gilead Lifesciences, Inc.: R&D, 2015-2021 (US$ million, AGR%) Figure 199 Novartis AG: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 200 Novartis AG: Regional Market Shares (%), 2021 Figure 201 Novartis AG: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 202 Novartis AG: R&D, 2015-2021 (US$ million, AGR %) Figure 203 Oxford Biomedica: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 204 Oxford Biomedica: Regional Market Shares (%), 2021 Figure 205 Pfizer, Inc.: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 206 Pfizer, Inc.: Regional Market Shares (%), 2021 Figure 207 Pfizer, Inc.: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 208 Pfizer, Inc.: R&D, 2015-2021 (US$ million, AGR%) Figure 209 REGENXBIO Inc.: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 210 REGENXBIO Inc.: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 211 REGENXBIO Inc.: R&D, 2015-2021 (US$ million, AGR%) Figure 212 Sangamo Therapeutics, Inc.: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 213 Sangamo Therapeutics, Inc.: Gross Profit, 2015-2021 (US$ million, AGR %) Figure 214 Sangamo Therapeutics, Inc.: R&D, 2015-2021 (US$ million, AGR%) Figure 215 Sanofi: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 216 Sanofi: Regional Market Shares (%), 2021 Figure 217 Sanofi: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 218 Sanofi: R&D, 2015-2021 (US$ million, AGR%) Figure 219 Takeda Pharmaceuticals: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 220 Takeda Pharmaceuticals: Regional Market Shares (%), 2021 Figure 221 Takeda Pharmaceuticals: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 222 Takeda Pharmaceuticals: R&D, 2015-2021 (US$ million, AGR%) Figure 223 UniQure NV: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 224 UniQure NV: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 225 UniQure NV: R&D, 2015-2021 (US$ million, AGR%) Figure 226 Voyager Therapeutics: Net Revenue, 2015-2021 (US$ million, AGR%) Figure 227 Voyager Therapeutics: Gross Profit, 2015-2021 (US$ million, AGR%) Figure 228 Voyager Therapeutics: R&D, 2015-2021 (US$ million, AGR%)
List of Companies Profiled in the report American Gene Technologies Applied Genetic Astellas Pharma Inc. Bayer Benitec BioPharma Biogen Bluebird Bio Bristol Myers Squibb Calimmune, Inc. (CSL Behiring) Cellectis F. Hoffmann-La Roche Ltd. GeneQuine Biotherapeutics GenSight Biologics Gilead Lifesciences, Inc. Novartis AG Ocugen, Inc. Orchard Therapeutics Oxford Biomedica Pfizer, Inc. REGENXBIO Inc. Sangamo Therapeutics, Inc. Sanofi Sarepta Therapeutics, Inc. Spark Therapeutics (Subsidiary of Roche) Takeda Pharmaceuticals Taysha GTx Transgene UniQure N. V. ViGeneron Voyager Therapeutics
List of Other Companies Mentioned in the report 4D Molecular Therapeutics Abeona Therapeutics Actus Therapeutics Adrenas Adverum Biotechnologies Akouos Amicus Therapeutics Apollo Therapeutics Aruvant Sciences Aspa Therapeutics Audentes AVROBIO Axovant Sciences Ltd BioVec Pharma Brainvectis SAS Catalyst Biosciences CavoGene Lifesciences Copernicus Therapeutics CRISPR Therapeutics AG Editas Medicine Enzo Biochem Errant Gene Therapeutics Esteve Pharmaceuticals SA Excision BioTherapeutics Exonics Therapeutics Expression Therapeutics Fibrocell Science Freeline Therapeutics Gemini Therapeutics Generation Bio Corp. Genethon SA GenSight Biologics SA Gyroscope Therapeutics Hemera Biosciences Holostem Terapie Avanzate Srl Homology Medicines Horama SA Immusoft Corp. iTherapeutics Corp. IVERIC bio Krystal Biotech Lamellar Biomedical Logicbio Therapeutics Lysogene Lysogene SAS/ Sarepta Therapeutics MeiraGTx Milo Biotechnology Mustang Bio NanoScope Technologies NeuExcell Therapeutics Nightstar Therapeutics/ Passage Bio Therapeutics PTC Therapeutics Renova Therapeutics Rocket Pharmaceuticals Rubius Therapeutics SanBio Co Tamid Bio Telocyte Temprian Therapeutics Tocagen Tolerion Ultragenyx Pharmaceutical ViroMed Co Ltd Vivet Therapeutics SAS
List of Associations Mentioned in the Report Gene Therapy Net Informa UK Limited IntechOpen JOURNAL OF GENERAL VIROLOGY Massachusetts Medical Society National Center for Biotechnology Information Pan European Networks Ltd Pharma Manufacturing Pharmaceutical-Networking.com The Alliance for Regenerative Medicine The Royal Society
Download sample pages
Complete the form below to download your free sample pages for Gene Therapy R&D Market Report 2022-2032
Factors such as rising prevalence of chronic and genetic diseases, increasing application areas of stem cell technologies, technological advancements, and...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
